If you aren’t losing weight with GLP-1 drugs, this may be one reason why

A 15,000-person genomic analysis identified variants in GLP1R and GIPR that modestly predict weight-loss response and nausea on GLP-1 drugs; ~10–15% of users are clinical non-responders. Carriers of one GLP1R variant lost ~1.5 lbs more and two copies ~>3 lbs more; for some with two copies this represented >10% of total study weight loss. 23andMe will add a report based on the findings to its $499 Total Health product, creating a potential commercial pathway for pharmacogenomic-guided prescribing.

Analysis

A genetic signal that differentiates responders from non-responders will push the obesity/diabetes drug market from broad-market volume to segmentation-driven economics. Expect manufacturers to invest in low-cost companion diagnostics and pricing stratification to protect launch pricing, with commercial playbooks shifting toward ‘test-and-treat’ bundles over the next 6–24 months. This will make the marginal dollar of new scripts more dependent on diagnostic uptake and payer acceptance than on headline demand alone.

Payers will quickly see an arbitrage: modest upfront diagnostic spend can reduce downstream drug spend and adverse-event churn. Within 12–18 months we can plausibly see step therapy adjustments, prior-authorization addenda, or conditional reimbursement pilots that carve out 10–30% of short-term addressable market in negotiated formularies — a dampener on topline growth but a lever to extract price concessions. That dynamic creates a binary catalyst pathway for manufacturers: either secure broad coverage by absorbing diagnostic costs or accept narrower, higher-value segments.

Diagnostics and CDMO suppliers are the obvious second-order beneficiaries and victims. Consumer-facing genetic vendors could capture a high-margin ancillary revenue stream if clinicians accept their reports, but they face regulatory, liability and privacy friction that could delay monetization by 12–36 months. Conversely, contract manufacturing names tied to scale-up may see uneven demand as treatment duration and eligible populations are redefined, amplifying inventory and working-capital volatility for smaller suppliers.

Key Decisions for Investors

• Long ME (23andMe) — 6–18 month horizon. Size 0.5–1% NAV or buy-to-open Jan 2027 calls (out-of-the-money). Thesis: capture productization/recurring revenue from diagnostic integration; upside if clinical adoption or payers accept reports; downside: regulatory/privacy backlash could compress value by 40–60%.
• Long LLY (Eli Lilly) — 12–24 month horizon via a directional call spread (buy-dated calls, sell higher strikes). Thesis: maintains leadership in therapeutic efficacy and pricing power if it bundles diagnostics or funds access; reward if it secures preferential formulary placement. Hedge with small UNH long to offset payer risks.
• Long UNH (UnitedHealth) — 12–24 months. Size 1–2% NAV. Thesis: payers will benefit from targeted prescribing and lower downstream costs; buy on pullbacks tied to short-term growth concerns. Risk: if diagnostics don’t affect utilization, upside is limited to incremental medical-cost savings.
• Short CTLT (Catalent) or small CDMO names — 6–18 months. Size small (0.25–0.5% NAV). Thesis: demand volatility and pricing pressure for peptide/biologic manufacturing as patient segmentation reduces steady-state volumes; risk: majors re-contracting or capacity tightness could reverse move quickly.